Advanced prostate cancer can initially be controlled with endocrine therapies that inhibit activity of the androgen receptor (AR), including androgen deprivation, the AR antagonist enzalutamide, and the androgen synthesis inhibitor abiraterone. This evidence concerns the gene AR and prostate carcinoma.